Terms: = Breast cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Treatment
23013 results:
1. Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4.
Santiso A; Heinemann A; Kargl J
Pharmacol Rev; 2024 May; 76(3):388-413. PubMed ID: 38697857
[TBL] [Abstract] [Full Text] [Related]
2. A novel preclinical model of the normal human breast.
Wilby AJ; Cabral S; Zoghi N; Howell SJ; Farnie G; Harrison H
J Mammary Gland Biol Neoplasia; 2024 May; 29(1):9. PubMed ID: 38695983
[TBL] [Abstract] [Full Text] [Related]
3. NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2.
Cardenas RP; Zyoud A; McIntyre A; Alberio R; Mongan NP; Allegrucci C
Stem Cell Res Ther; 2024 May; 15(1):128. PubMed ID: 38693576
[TBL] [Abstract] [Full Text] [Related]
4. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
5. [Identification of Protein-Coding Gene Markers in breast Invasive Carcinoma Based on Machine Learning].
Wu Y; Min KY; Liu JF; Liang WF; Yang YH; Hu G; Yang JT
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):147-153. PubMed ID: 38686709
[TBL] [Abstract] [Full Text] [Related]
6. Neoadjuvant Chemotherapy in Patients with HER2-Negative breast cancer: A Report from Clinical breast cancer Registry of Iran.
Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
[TBL] [Abstract] [Full Text] [Related]
7. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
8. In Vitro Antiviral and Anticancer Effects of Tanacetum sinaicum Essential Oil on Human Cervical and breast cancer.
Sheashea AA; Ahmed FA; El Zayat E; Ebeed BW; Elberry MH; Hassan ZKM; Hafez MM
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1457-1471. PubMed ID: 38680008
[TBL] [Abstract] [Full Text] [Related]
9. Characterization of the prognostic, diagnostic, and immunological roles of DSCC1 and its genomic alteration and instability in human cancers.
Liu H; Cui Z; Wang R; Wang L; Wang L; Cheng F; Pan R; Yang X
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):202-211. PubMed ID: 38678604
[TBL] [Abstract] [Full Text] [Related]
10. A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy.
Ascheid D; Baumann M; Pinnecker J; Friedrich M; Szi-Marton D; Medved C; Bundalo M; Ortmann V; Öztürk A; Nandigama R; Hemmen K; Ergün S; Zernecke A; Hirth M; Heinze KG; Henke E
Nat Commun; 2024 Apr; 15(1):3599. PubMed ID: 38678014
[TBL] [Abstract] [Full Text] [Related]
11. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
Han JY; Che N; Mo J; Zhang DF; Liang XH; Dong XY; Zhao XL; Sun BC
BMC Cancer; 2024 Apr; 24(1):532. PubMed ID: 38671389
[TBL] [Abstract] [Full Text] [Related]
12. Deep Learning Prediction of Axillary Lymph Node Metastasis in breast cancer Patients Using Clinical Implication-Applied Preprocessed CT Images.
Park TY; Kwon LM; Hyeon J; Cho BJ; Kim BJ
Curr Oncol; 2024 Apr; 31(4):2278-2288. PubMed ID: 38668072
[No Abstract] [Full Text] [Related]
13. Real-World treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic breast cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract] [Full Text] [Related]
15. Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer.
Eiro N; Fraile M; Escudero-Cernuda S; Sendon-Lago J; Gonzalez LO; Fernandez-Sánchez ML; Vizoso FJ
Stem Cell Res Ther; 2024 Apr; 15(1):121. PubMed ID: 38664697
[TBL] [Abstract] [Full Text] [Related]
16. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract] [Full Text] [Related]
17. Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation.
Aboomar NM; Essam O; Hassan A; Bassiouny AR; Arafa RK
Sci Rep; 2024 Apr; 14(1):9386. PubMed ID: 38653790
[TBL] [Abstract] [Full Text] [Related]
18. Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression.
Shaban N; Raevskiy M; Zakharova G; Shipunova V; Deyev S; Suntsova M; Sorokin M; Buzdin A; Kamashev D
Biochemistry (Mosc); 2024 Mar; 89(3):487-506. PubMed ID: 38648768
[TBL] [Abstract] [Full Text] [Related]
19. Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma.
Sarogni P; Brindani N; Zamborlin A; Gonnelli A; Menicagli M; Mapanao AK; Munafò F; De Vivo M; Voliani V
Sci Rep; 2024 Apr; 14(1):9150. PubMed ID: 38644364
[TBL] [Abstract] [Full Text] [Related]
20. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
[TBL] [Abstract] [Full Text] [Related]
[Next]
